Located just outside WASHINGTON DC
, The Degge Group
provides consulting services to the biopharmaceutical and medical
products sector specializing in clinical drug safety,
pharmacovigilance, medical product epidemiology, and risk management.
Degge's staff has contributed to the burgeoning fields of
pharmacoepidemiology and pharmacovigilance for over two decades and
has worked to enhance the understanding of drug safety, drug use,
natural history of disease studies, risk evaluation and mitigation
strategies (REMS), benefit-risk assessments, and pharmacoeconomic and
Degge will help you identify and analyze key data to meet your needs.
- As of April 24, 2017, The Degge Group, Ltd. has become a member of PharmaLex GmbH (Friedrichsdorf, Germany), an international consortium of small companies similar to Degge but with different areas of scientific expertise and focus in the biopharma industry. We are pleased about joining PharmaLex’s group of companies. The impact of Degge’s joining PharmaLex will primarily be felt in our Research and Regulatory Consulting Divisions, which will be enhanced by additional PharmaLex expertise and services. Read More
- Degge’s latest publication, Long-term risk of reproductive cancer among Vietnamese women using the quinacrine hydrochloride pellet system vs. intrauterine devices or tubal ligation for contraception appears in the current online version of The European Journal of Contraception & Reproductive Health Care (Volume 22, Issue 2). Authored by Degge President and CEO Judith K Jones, MD, PhD, FISPE, with co-authors Arlene Tave, MA (Degge), John Pezzullo, PhD (deceased) formerly of Georgetown University Department of Biomathematics and Biostatistics, Sharon Kardia, PhD of the University of Michigan School of Public Health, and Jack Lippes, MD of the State University of New York at Buffalo Department of Obstetrics and Gynecology, the article reports on a large retrospective cohort study in Vietnam that Degge helped design and independently analyzed. The study demonstrated that there was no excess long-term risk of reproductive tract cancers associated with use of the quinacrine hydrochloride pellet system of contraception. The print version of the publication will be available in late March or early April, 2017. For questions, please contact Arlene Tave at firstname.lastname@example.org
- Our recent publication: Intranasal Fluticasone Propionate Observational Cohort Safety Studies: Reviewing Evidence from Databases on Two Continents” was recently published with open access in Drugs – Real World Outcomes. Coauthors included Earl Goehring Jr, and Judith K Jones, MD, PhD, FISPE.